Dr. Ohidul Alam | Oncology Case Reports | Best Researcher Award

Posted on by Pencis

Dr. Ohidul Alam | Oncology Case Reports | Best Researcher Award

Jiangsu University | China

Author Profile

Scopus

Google Scholar

🌍 Dr. Ohidul Alam: Postdoctoral Research Fellow and Environmental Innovator 🌱

💧Current Position

  • Postdoctoral Research Fellow, Institute of Environment and Ecology, School of the Environment and Safety Engineering, Jiangsu University

♻️Research Focus

Dr. Ohidul Alam is dedicated to advancing environmental sustainability and ecological safety. His primary research interests include:

  • 🌊 Coastal Environment and Wetlands: Investigating microplastics as vectors for antibiotic resistance genes (ARGs) and heavy metals.
  • ♻️ Hazardous Waste Management: Treatment and recycling of waste and heavy metals.
  • 💧 Wastewater Treatment and Pollution Control: Developing advanced environmental materials like adsorbents and composites for energy storage and purification.
  • 🧬 Antibiotic Resistance Genes: Exploring ARG mechanisms in ecological systems.

🎓Education 

  • PhD in Environmental Engineering, East China University of Science and Technology, Shanghai, China (2016–2021)
  • MEng in Environmental Engineering, UNEP-Tongji Institute of Environment for Sustainable Development, Tongji University, Shanghai, China (2014–2016)
  • MS in Environmental Science, Institute of Forestry and Environmental Sciences, University of Chittagong, Bangladesh (2010–2011)

🛠Career Snapshot 

  • Postdoctoral Research (2023–Present): Investigating microplastics as vehicles for ARGs and toxic heavy metals in coastal wetlands, assessing ecological and health risks.
  • Environmental Officer (2022–2023): Sustainable Enterprise Project (SEP), Integrated Development Foundation (IDF).
  • Research Associate and Assistant: Contributed to seven major academic and socio-environmental projects.

🖋Publications and Contributions 

  • Published 15 SCI-indexed journal papers, 9 international open-access journal articles, and 13 international conference papers.
  • Authored 3 national journal articles and 3 technical/working papers.
  • Supported colleagues in research, thesis writing, and scientific publications.

🏆Recognition and Awards 

  • Chinese Scholarship Council (CSC) and Marine Scholarship of China (MSC), 2014
  • Tongji University President Scholarship (2nd Prize), 2015, for academic excellence.

🤝Professional Memberships 

  • International Waste Working Group (IWWG)
  • Human Development Foundation (HDF)

🧾Reviewer Roles 

  • Journal of Environmental Management
  • Environmental Research
  • Environment, Development and Sustainability
  • Water Science and Technology

📚Training and Skills Development 

  • Completed advanced training on the Leaching Environmental Assessment Framework (LEAF) for waste treatment and beneficial reuse.

Dr. Alam’s interdisciplinary approach bridges the gap between environmental engineering, sustainable development, and ecological safety. His work continues to inspire progress toward a cleaner, safer world. 🌍✨

🌏 CONCLUSION

Dr. Ohidul Alam exemplifies dedication to environmental sustainability through his groundbreaking research on hazardous waste management, pollution control, and ecological risks posed by microplastics. His extensive academic achievements, impactful publications, and hands-on contributions to global environmental projects highlight his expertise and commitment to creating sustainable solutions for pressing environmental challenges. As a scholar, innovator, and mentor, Dr. Alam continues to pave the way for a cleaner, safer, and more sustainable future. 🌱🌍

📊🔬NOTABLE PUBLICATION:
  • Title: An in-depth review on municipal solid waste management, treatment, and disposal in Bangladesh
    • Authors: Alam, O.; Qiao, X.
    • Journal: Sustainable Cities and Society
    • Year: 2020

 

  • Title: A preliminary life cycle assessment on healthcare waste management in Chittagong City, Bangladesh
    • Authors: Alam, O.; Mosharraf, A.
    • Journal: International Journal of Environmental Science and Technology
    • Year: 2020

 

  • Title: Influences of chemically controlled Ca-bearing minerals in chitosan on Pb²⁺ removal efficiency
    • Authors: Alam, O.; Qiao, X.
    • Journal: Journal of Environmental Health Science and Engineering
    • Year: 2020

 

  • Title: The effect of Ca-bearing contents in chitosan on Pb²⁺, Cd²⁺, and Cu²⁺ adsorption and its adsorption mechanism
    • Authors: Alam, O.; Qiao, X.; Nath, T.K.
    • Journal: Journal of Environmental Health Science and Engineering
    • Year: 2020

 

  • Title: Remediation of heavy metals polluted soil environment: A critical review on biological approaches
    • Authors: Zheng, X.; Lin, H.; Du, D.; Jiang, S.; Li, J.
    • Journal: Ecotoxicology and Environmental Safety
    • Year: 2024

Mr. Toshitaka Hirano | Malignancy | Best Researcher Award

Posted on by Pencis

Mr. Toshitaka Hirano | Malignancy | Best Researcher Award

Pfizer Japan Inc | Japan

AUTHOR PROFILE

ORCID ID

🏫 EARLY ACADEMIC PURSUITS

Mr. Toshitaka Hirano pursued his education in Japan, specializing in fields related to oncology and pharmaceutical sciences. His early academic years were marked by a strong commitment to understanding the mechanisms of malignancy and its risk factors, laying the foundation for his influential career.

💼 PROFESSIONAL ENDEAVORS

Currently associated with Pfizer, Mr. Hirano has established himself as a leading expert in the risk factor analysis of malignancy. His role includes conducting advanced research, collaborating with global teams, and integrating pharmaceutical innovation with clinical practice.

🧬 CONTRIBUTIONS AND RESEARCH FOCUS

Mr. Hirano’s research is focused on identifying malignancy risk factors, particularly in patients with chronic conditions like rheumatoid arthritis. His studies examine the interplay between biological, environmental, and genetic factors contributing to cancer development. He has significantly advanced understanding in areas such as:

  • Immunogenicity risk associated with biologics
  • Cardiovascular events in rheumatic disease patients
  • Safety and effectiveness of novel therapies like tofacitinib

🌏 IMPACT AND INFLUENCE

Mr. Hirano’s work has had a profound impact on both clinical and research landscapes:

  • Policy and Practice: His findings inform public health guidelines and pharmaceutical strategies.
  • Patient Outcomes: Through his research, he has contributed to safer and more effective treatments for vulnerable populations.
  • International Collaboration: His global outreach ensures the dissemination of knowledge and best practices.

📚 ACADEMIC CITES

Mr. Hirano’s scholarly work is widely cited in high-impact journals, demonstrating its relevance and importance. Key publications include articles in International Journal of Rheumatic Diseases, Frontiers in Immunology, and Modern Rheumatology, highlighting his expertise in malignancy risk within rheumatic populations.

🏆 LEGACY AND FUTURE CONTRIBUTIONS ON MALIGNANCY

As a trailblazer in the field, Mr. Hirano is building a legacy of innovation and dedication to improving cancer outcomes. His future efforts aim to:

  • Develop predictive models for malignancy risks.
  • Enhance personalized medicine approaches.
  • Mentor the next generation of researchers in oncology and pharmaceutical sciences.

📌 OTHER IMPORTANT TOPICS

🔍 INTERDISCIPLINARY INTEGRATION

Mr. Hirano’s work bridges multiple fields, including oncology, immunology, and rheumatology, showcasing the value of a holistic research approach.

🌟 MENTORSHIP AND TEAM LEADERSHIP

He plays an active role in guiding young researchers and fostering collaborative environments that drive innovation.

🔔 PATIENT-CENTERED FOCUS

By emphasizing real-world data and patient-centered outcomes, Mr. Hirano ensures his work directly benefits those in need.

✨ CONCLUSION

Mr. Toshitaka Hirano’s dedication to malignancy risk analysis exemplifies the power of focused research to drive meaningful change. His work at Pfizer and beyond demonstrates a commitment to innovation, collaboration, and improving global health. With a legacy rooted in impactful research and a vision for a healthier future, Mr. Hirano continues to inspire and lead in the fight against cancer.

📊🔬NOTABLE PUBLICATION:
  • 1️⃣ Risk Factors Associated With Major Adverse Cardiovascular Events and Malignancies in Patients With Rheumatoid Arthritis in a Real-World Setting in Japan
    • Authors: Kunihiro Yamaoka, Sugiyama N, Hoshi M, Jo JY, Kichul Shin, Hirano T
    • Journal: International Journal of Rheumatic Diseases
    • Year: 2024

    2️⃣ Individual and Population-Level Variability in HLA-DR Associated Immunogenicity Risk of Biologics Used for the Treatment of Rheumatoid Arthritis

    • Authors: Sugiyama N, Terry FE, Gutierrez AH, Hirano T, Hoshi M, Mizuno Y, Martin W, Yasunaga S, Niiro H, Fujio K, et al.
    • Journal: Frontiers in Immunology
    • Year: 2024

    3️⃣ Six-Month Safety and Effectiveness of Tofacitinib in Patients With Rheumatoid Arthritis in Japan: Interim Analysis of Post-Marketing Surveillance

    • Authors: Masataka Kuwana, Sugiyama N, Momohara S, Atsumi T, Takei S, Naoto Tamura, Masayoshi Harigai, Fujii T, Matsuno H, Takeuchi T, et al.
    • Journal: Modern Rheumatology
    • Year: 2024

Dr. Salem Baldi | Cancer Diagnosis | Best Researcher Award

Posted on by Pencis

Dr. Salem Baldi | Cancer Diagnosis | Best Researcher Award

Shaoyang University | China

Author Profile

Scopus

ORCID ID

Google Scholar

🌍Dr. Salem Baldi, Ph.D.
Associate Professor, Medical Laboratory Diagnostics🔬:

🧬Biography:

Dr. Salem Baldi is an esteemed Associate Professor at the Department of Medical Laboratory Diagnostics, Shaoyang University, China. With a strong background in biochemistry, molecular biology, and clinical diagnostics, he has made noteworthy contributions to cancer research and genetic diagnostics 🧬. He previously worked as a Biochemistry Research Scientist at Anxuyuan Biotechnology in Shenzhen, where he applied his expertise in molecular diagnostics.

Dr. Baldi holds a Ph.D. in Clinical Laboratory Diagnostics from Dalian Medical University and a Master’s in Molecular Genetics from Jiamusi University, China. His research expertise spans cancer cell biology, DNA library preparation, and advanced genetic techniques such as CRISPR/Cas9 for disease modeling. 🧫

Fluent in English, Arabic, and Chinese, Dr. Baldi is deeply engaged in the global scientific community, holding memberships in the European Society for Blood and Marrow Transplantation and the Arab Society of Genetic Counselors. His remarkable dedication to science has earned him numerous awards, recognizing his impact in both academic and scientific circles. 🏅

Beyond his professional life, Dr. Baldi enjoys soccer, badminton, tennis, traveling, reading, and gardening ⚽🌿📚.

🧪Research Interests:

  • Cancer Diagnostics 🧫
  • Molecular Genetics 🧬
  • Clinical Laboratory Science 🧪
  • Innovative Approaches in Medical Research 🌱

📊Skills & Expertise:

  • Mammalian Cell Culture (Primary and Cancer Cells)
  • Molecular Cloning, Transfection, Gene Expression
  • PCR, qPCR, Real-Time PCR 🔬
  • Western Blotting, SDS-PAGE, Immunofluorescence
  • DNA Library Preparation (NGS, Illumina, PacBio) 📊
  • CRISPR/Cas9 Disease Modeling 🧬

🏅Awards & Recognitions:

  • 2021: Excellence in Scientific Research 🏅, Yemeni Ministry of Higher Education
  • 2022: Certificate of Gratitude 🙏, Yemeni Students Union, China

🌍Languages:

  • English
  • Arabic
  • Chinese

✨Conclusion:

🌱Dr. Salem Baldi is a dedicated researcher and educator, committed to advancing the field of medical laboratory diagnostics. His expertise in molecular biology and biochemistry, coupled with a global perspective and fluency in multiple languages, positions him as a leader in cancer research and diagnostics. His passion for integrating traditional and modern medical practices drives his innovative approach to improving patient outcomes. Beyond the lab, his diverse interests reflect a well-rounded individual who is deeply engaged in both his personal and professional pursuits. ✨

📊🔬NOTABLE PUBLICATION:

  • Surgery improves survival in bladder signet-ring cell carcinoma-a population-based study
    Authors: Alradhi, M., Safi, M., Tao, S., Baldi, S., Li, X.
    Journal: Therapeutic Advances in Urology
    Year: 2022

 

  • Immune Checkpoint Inhibitor (ICI) Genes and Aging in Clear Cell Renal Cell Carcinoma (ccRCC): Clinical and Genomic Study
    Authors: Al-Danakh, A., Safi, M., Alradhi, M., Zhu, X., Yang, D.
    Journal: Cells
    Year: 2022

 

  • ARID1A downregulation promotes cell proliferation and migration of colon cancer via VIM activation and CDH1 suppression
    Authors: Baldi, S., Zhang, Q., Zhang, Z., Al-Nusaif, M., Zuo, Y.
    Journal: Journal of Cellular and Molecular Medicine
    Year: 2022

 

  • Novel characterization discoveries of ferroptosis-associated molecules in COAD microenvironment based TCGA data
    Authors: Baldi, S., He, Y., Ivanov, I., Gao, Y., Tian, H.
    Journal: Frontiers in Molecular Biosciences
    Year: 2022

 

  • Unraveling the salt tolerance of Phi29 DNA polymerase using compartmentalized self-replication and microfluidics platform
    Authors: Sun, Y., Ko, D.H., Gao, J., He, Y., Tian, H.
    Journal: Frontiers in Microbiology
    Year: 2023

Prof. IsabellaCavalcanti – Cancer Science – Best Researcher Award

Posted on by Pencis

Prof. IsabellaCavalcanti - Cancer Science - Best Researcher Award

Federal University of Pernambuco (UFPE) - Brazil

Author Profile

Google Scholar 

Scopus

Orcid

EARLY ACADEMIC PURSUITS

Isabella Macário Ferro Cavalcanti began her academic journey by graduating in Biomedicine from the Federal University of Pernambuco (UFPE). Following this, she pursued a master's degree in Therapeutic Innovation at UFPE, delving into advanced studies in the field. She then proceeded to earn her doctorate in Biotechnology, further refining her expertise in biological sciences.

PROFESSIONAL ENDEAVORS

Dr. Cavalcanti's professional career has been marked by significant accomplishments. She specializes in Clinical Microbiology, obtaining further specialization at the University of Pernambuco (UPE). Currently, she serves as a professor at UFPE, where she contributes to the education and training of future professionals in the field. Her involvement extends to leadership roles within various post-graduate programs, emphasizing her dedication to academic advancement.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER SCIENCE

Dr. Cavalcanti's research endeavors are diverse and impactful. As the Head and Researcher of Clinical Microbiology at the Laboratory of Immunopathology Keizo Asami at UFPE (LIKA/UFPE), she spearheads investigations into drug delivery systems and their biological activities. Her research group, MicroNAT, focuses on innovative approaches to combat multi-drug-resistant bacteria and biofilm formation. Through her work, she seeks to advance pharmaceutical nanotechnology and fundamental microbiological understanding.

IMPACT AND INFLUENCE

Isabella Macário Ferro Cavalcanti's contributions have had a profound impact on the fields of pharmaceutical nanotechnology and microbiology. Her research findings contribute to the development of novel therapeutic strategies and the understanding of microbial resistance mechanisms. As a respected member of the Brazilian Society of Microbiology and various scientific committees, her expertise is recognized nationally and internationally.

ACADEMIC CITATIONS

Dr. Cavalcanti's work has garnered significant attention within the academic community, reflected in numerous citations of her research publications. Her contributions to scientific literature serve as a foundation for further exploration and innovation in the fields of biotechnology, microbiology, and drug delivery.

LEGACY AND FUTURE CONTRIBUTIONS

With a strong foundation in academia and research, Dr. Cavalcanti's legacy is marked by her dedication to advancing knowledge and addressing critical healthcare challenges. Her leadership in research groups and academic programs ensures the continued development of future scientists and the pursuit of innovative solutions to complex biomedical problems. As she continues her career, her contributions are poised to further shape the landscape of biomedicine and microbiology, leaving a lasting legacy of excellence and innovation.

NOTABLE PUBLICATIONS

Zein nanoparticles containing ceftazidime and tobramycin: antibacterial activity against Gram-negative bacteria. 2024

Proteomic characterization and biological activities of the mucus produced by the zoanthid Palythoa caribaeorum (Duchassaing & Michelotti, 1860) 2023

Efficacy and non-toxicity of ciclopirox olamine-loaded liposomes against Cryptococcus neoformans clinical isolates. 2023

Gram-negative bacilli carrying mcr gene in Brazil: a pathogen on the rise. 2023

Antibiotic resistance profiles on pathogenic bacteria in the Brazilian environments. 2023

Prof Dr.Sheeren Mohammed Khaled – Cancer Science – Best Researcher Award

Posted on by Pencis

Prof Dr.Sheeren Mohammed Khaled - Cancer Science - Best Researcher Award

King Abdullah Medical City - Saudi Arabia

AUTHOR PROFILE

Scopus

Orcid

EARLY ACADEMIC PURSUITS:

Dr. Sheeren Mohammed Khaled began her academic journey with a Bachelor of Medicine and Surgery (M.B., B.Ch.) from Benha University, Faculty of Medicine, graduating with excellence in December 2005. Following this, she pursued her Master's degree in Cardiology at Benha University, graduating with a very good grade in September 2010. Dr. Khaled continued her academic endeavors, earning her MD degree in Cardiology from Benha University in May 2014.

PROFESSIONAL ENDEAVORS:

Dr. Khaled's professional journey reflects a rich and diverse experience in the field of Cardiology: Consultant Cardiology at King Abdullah Medical City (KAMC), Associate Professor of Cardiology at Benha University, Lecturer of Cardiology at Benha University Hospital, Associate Consultant Cardiology at KAMC, Cardiology Specialist at Alzahra Hospital (Saudi Arabia), Assistant Lecturer at Benha University Hospital.

IMPACT AND INFLUENCE ON CANCER SCIENCE

Dr. Sheeren Mohammed Khaled has made significant contributions to the field of cancer science through her roles as a clinician, educator, and researcher. Her commitment to teaching, clinical excellence, and research activities has had a positive impact on both students and colleagues.

ACADEMIC CITATIONS:

Dr. Khaled's academic citations are reflective of her contributions to research studies, the supervision of theses, and active involvement in various scientific committees.

LEGACY AND FUTURE CONTRIBUTIONS:

Dr. Sheeren Mohammed Khaled's legacy lies in her dedication to advancing cardiology education, patient care, and research. Her future contributions are anticipated to further enrich the field through continued excellence in teaching, clinical practice, and impactful research initiatives.

NOTABLE PUBLICATIONS

Myocardial recovery after percutaneous coronary intervention in coronary artery disease patients with impaired systolic function- predictive utility of global longitudinal strain.2022

Severe Left Ventricular Dysfunction Earlier after Acute Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention: Predictors and In-Hospital Outcome– A Middle Eastern Tertiary Center Experience.2023

Cardiogenic Shock Among Patients with Acute ST-Segment Elevation Myocardial Infarction in a Middle Eastern Country: A Single-Center Experience.2023